{"entity":{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","aka":[],"tldr":"Cancer that has spread to only a few places, which may still be curable by treating each spot.","summary":"Oligometastatic disease is cancer that has spread to only a few sites, usually no more than three to five metastases, and may still be curable if each spot is treated. The SABR-COMET trial supported metastasis-directed SBRT / SABR (stereotactic radiotherapy), and the ESTRO/EORTC classification distinguishes synchronous, oligorecurrent and oligoprogressive disease, the last covered by the related term Oligoprogression. PSMA PET has expanded detection of this state in Prostate cancer, and the term is also referenced by the Renal cell carcinoma entry and the bottleneck on metastasis biology. Ideas building on it include PSMA-PET-guided metastasis-directed therapy as a curative strategy and a test to tell true oligometastatic disease from hidden widespread spread.","asOf":"2026-09-04","links":[{"label":"NCI Dictionary of Cancer Terms: oligometastasis","url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/oligometastasis"},{"label":"Lievens et al., Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus (Radiotherapy and Oncology 2020)","url":"https://doi.org/10.1016/j.radonc.2020.04.003"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":["psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/oligometastatic/","neighbours":{"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"indication":[{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/"}],"idea":[{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/"},{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/"}]}}